XCUR News and Press, Exicure Inc. From 09/01/22

Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will pr...

Exicure press release ( NASDAQ: XCUR ): Q2 GAAP EPS of -$1.66 (vs. -$4.86 Y/Y). Revenue of $2.5M (vs. $0.1M Y/Y). Shares -9.05% AH. For further details see: Exicure Q2 GAAP loss per share narrows, revenue up

Company advancing SCN9A preclinical discovery program Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological and hair loss diso...

Euro Tech Holdings Company ( CLWT ) +39% . SilverSun Technologies ( SSNT ) +28% . Aethlon Medical ( AEMD ) +19% CEO Chuck Fisher on Q1 2023 Results - Earnings Call Transcript. The Trade Desk ( TTD ) +16% Inc. 2023 Q2 - Results - Earnings C...

Hyzon Motors ( HYZN ) -36% after disclosing operational inefficiencies, financial issues . Helius Medical Technologies ( HSDT ) -30% . Quoin Pharmaceuticals ( QNRX ) -23% . Chembio Diagnostics ( CEMI ) -18% on Q2 earnings release . ...

InVivo Therapeutics Holdings ( NVIV ) +106% . GreenLight Biosciences ( GRNA ) +94% . NanoViricides ( NNVC ) +48% stock skyrockets 50% on start of drug development program for monkeypox. Exicure ( XCUR ) +39% . Global Blood Therapeuti...

Nasdaq has informed Exicure ( NASDAQ: XCUR ) that the biotechnology company has regained compliance with the stock exchange's $1.00 per share minimum bid price requirement. XCUR is now in compliance with all applicable listing standards, and the company's shares will ...

Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it receive...

Exicure ( XCUR ) on Monday filed a shelf registration covering 867,369 ordinary shares for selling stockholders. This prospectus is not an offer to sell these securities. XCUR -7.8% premarket to $1.93. For further details see: Exicure files shelf registr...

Gainers: NeuroSense Therapeutics ( NRSN ) +53% . Rapid Micro Biosystems ( RPID ) +36% . Burning Rock Biotech ( BNR ) +15% . Tyra Biosciences ( TYRA ) +7% . Addex Therapeutics ( ADXN ) +5% . Losers: Renalytix ( RNLX ) -40% ...